Glycan-mediated modification of the immune response

OncoImmunology

Volumn 2, Issue 4, 2013, Pages

  Madsen, Caroline B ^a   Pedersen, Anders E ^a   Wandall, Hans H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

C type lectins; Carbohydrate receptors; Dendritic cells; GalNAc; Glycans; Vaccines

Indexed keywords

CANCER VACCINE; GLYCAN; IMMUNOGLOBULIN M; LECTIN; TOLL LIKE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CYTOKINE RELEASE; DENDRITIC CELL; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LYMPHOCYTE ACTIVATION; PHAGOCYTOSIS; PROTEIN MODIFICATION;

EID: 84886945651     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23659     Document Type: Article

References (10)

1. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009; 9:465-79; PMID:19521399; http://dx.doi.org/10.1038/nri2569
2. Pedersen JW, Blixt O, Bennett EP, Tarp MA, Dar I, Mandel U, et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer 2011; 128:1860-71; PMID:21344374; http://dx.doi.org/10.1002/ijc.25778
3. Adams EW, Ratner DM, Seeberger PH, Hacohen N. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells. Chembiochem 2008; 9:294-303; PMID:18186095; http://dx.doi.org/10.1002/cbic.200700310
4. Unger WW, van Kooyk Y. 'Dressed for success' C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells. Curr Opin Immunol 2011; 23:131-7; PMID:21169001; http://dx.doi.org/10.1016/j.coi.2010.11.011
5. Madsen CB, Petersen C, Lavrsen K, Harndahl M, Buus S, Clausen H, et al. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response. PLoS One 2012; 7:e50139; PMID:23189185; http://dx.doi.org/10.1371/journal.pone.0050139
6. Napoletano C, Rughetti A, Agervig Tarp MP, Coleman J, Bennett EP, Picco G, et al. Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res 2007; 67:8358-67; PMID:17804752; http://dx.doi.org/10.1158/0008-5472.CAN-07-1035
7. Singh SK, Streng-Ouwehand I, Litjens M, Kalay H, Saeland E, van Kooyk Y. Tumour-associated glycan modifications of antigen enhance MGL2 dependent uptake and MHC class I restricted CD8 T cell responses. Int J Cancer 2011; 128:1371-83; PMID:20473945; http://dx.doi.org/10.1002/ijc.25458
8. Ninkovic T, Hanisch FG. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes. J Immunol 2007; 179:2380-8; PMID:17675499
9. Apostolopoulos V, Yuriev E, Ramsland PA, Halton J, Osinski C, Li W, et al. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci U S A 2003; 100:15029-34; PMID:14657390; http://dx.doi.org/10.1073/pnas.2432220100
10. Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A 2012; 109:261-6; PMID:22171012; http://dx.doi.org/10.1073/pnas.1115166109